Iris Dorbian
San Diego-based BioClarity, a skincare brand, has secured $13 million in funding. Prolog Ventures led the round.
San Diego-based BioClarity, a skincare brand, has secured $13 million in funding. Prolog Ventures led the round.
San Francisco-based Phil Inc, a technology platform for distributing and managing specialty prescription drugs, has raised $25 million in Series B funding. GreatPoint Ventures led the round with participation from Tarsadia Investments, Crosslink Capital and Uncork Capital.
Phoenix-based Solera Health, a health network, has secured $42 million in Series C funding. HCSC Ventures led the round.
Phoenix-based Solera Health, a health network, has secured $42 million in Series C funding. HCSC Ventures led the round.
Seattle-based Karat, which conducts technical interviews on behalf of companies, has raised $28 million in Series B funding. Tiger Global Management led the round with participation from return backers Norwest Venture Partners and 8VC.
Seattle-based Karat, which conducts technical interviews on behalf of companies, has raised $28 million in Series B funding. Tiger Global Management led the round with participation from return backers Norwest Venture Partners and 8VC.
Brooklyn, New York-based Zipari, an insurance software startup, has named Mark Poling as chief product officer. Zipari is backed by Vertical Venture Partners.
Menlo Park, California-based Phathom Pharmaceuticals, a newly launched biopharmaceutical company focused on treating gastrointestinal diseases and disorders, has secured $90 million in funding. Frazier Healthcare Partners led the round with participation from other investors that included Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen. Also, Phathom has secured a $50 million term loan facility from Silicon Valley Bank.
Menlo Park, California-based Phathom Pharmaceuticals, a newly launched biopharmaceutical company focused on treating gastrointestinal diseases and disorders, has secured $90 million in funding. Frazier Healthcare Partners led the round with participation from other investors that included Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen. Also, Phathom has secured a $50 million term loan facility from Silicon Valley Bank.